

Friday, 14th of January 2022
Scientific Business Meeting Programme
(Working Party members only)

09.00 – 09.45	Welcome	
09.45 – 10.00	Introduction	Ibrahim Yakoub-Agha Patrick Hayden
10.00 – 11.10	Plasma cell disorders subcommittee projects presentation	Stefan Schönland Meral Beksac
11.10 – 11.40	Break	
11.40 – 12.50	PH-negative myeloproliferative syndromes subcommittee projects presentation	Donal McLornan Tomasz Czerw Juan Carlos Hernandez Boluda
12.50 – 13.30	Chronic myeloid leukemia subcommittee projects presentation	Yves Chalandon
13.30 – 14.15	Break	
14.15 – 14.30	VEXAS Study	Marie Robin
14.30 – 15.30	Myelodysplastic syndromes including CMML subcommittee projects presentation	Marie Robin Francesco Onida Christof Scheid
15.30 – 16.00	Chronic lymphoid leukemia subcommittee projects presentation	Olivier Tournilhac Michel Van Gelder
16.00 – 16.15	Nursing participation in the CMWP	Maaïke de Ruijter
16.15 – 16.45	Break	
16.45 – 17.00	An update on EBMT registry	Johannes Schetelig Carina Gross
17.00 – 17.30	Practice harmonisation and guidelines subcommittee	Patrick Hayden Laurent Garderet
17.30 – 17.40	Closing remarks	

Saturday, 15th of January 2022
Educational Meeting Programme

09.00 – 09.10	Introduction	Ibrahim Yakoub-Agha Patrick Hayden
09.10 – 10.00	Session I: MPN Chair: T Czerw	
09.10 – 09.30	ASH 2021 Update	Donal McLornan
09.30 – 10.00	Debate – Is 70 years the upper age limit for alloSCT in MF? YES NO	Juan Carlos Hernández Nicola Polverelli
10.00 – 10.50	Session II: Multiple myeloma Chair: L Garderet	
10.00 - 10.20	ASH 2021 Update	Patrick Hayden
10.20 - 10.50	Debate – Is myeloma now a curable disease? YES NO	Roberto Mina Meral Beksac
10.50 – 11.30	Break	
11.30 – 12.20	Session III: MDS Chair: I Yakoub-Agha	
11.30 – 11.50	ASH 2021 Update	Ibrahim Yakoub-Agha
11.50 – 12.20	Debate – Should we offer alloSCT to MDS pt with high risk cytogenetics? YES NO	Christof Scheid Xavier Poire
12.20 – 13.00	Break	
13.00 – 13.30	Session IV: Statistics and Data Management	
13.00 – 13.30	Testing for equivalence or non-inferiority	Luuk Gras
13.30 – 14.30	Session V: CMML Chair: F. Onida	
13.30 – 13.50	ASH 2021 Update	Francesco Onida
13.50 – 14.10	Debate – Should we offer alloHCT for patients with CMML? YES NO	Theo de Witte Raphael Itzykson
14.10 – 14.30		
14.30 – 14.40	Conclusion	